Halozyme raises 2025 guidance, announces $250M stock buyback
Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Halozyme’s Strategic Growth and Financial Strength Boosts Buy Rating
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...
Halozyme raises FY25 adjusted EPS view to $4.95-$5.35 from $4.45-$4.85
FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.Stay Ahead of the Market:Discover ...
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage ...
Investor's Business Daily on MSN1h
SpringWorks Therapeutics Stock Gets A RS Rating Lift
SpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...
marketinference3h
HALO Surges – What's Behind the Rally?
Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...
Greek Reporter21h
Greek News
The traditional carnival-like "Ragoutsaria" celebration is wrapping up today, January 8, in the city of Kastoria, northern Greece, seeing locals donning colorful costumes and dancing in the streets of ...